mSMART Plasma Cell Proliferative Disorder, Pre-Analysis Cell Sorting, Bone Marrow
Use
The test is used for risk stratification of patients with multiple myeloma, which facilitates decisions regarding treatment and management. It involves sorting plasma cells for fluorescence in situ hybridization (FISH) analysis and is pertinent for patients with newly diagnosed multiple myeloma, offering insights into cytogenetic and molecular heterogeneity and disease aggressiveness.
Special Instructions
This test is not orderable standalone; it is only orderable as a reflex following other tests such as the Mayo Algorithmic Approach for Stratification of Myeloma and Risk-Adapted Therapy Report (MSMRT) and Myeloma Stratification and Risk-Adapted Therapy with Reflex to Minimal Residual Disease (MSMRD). It's crucial to handle and send the specimen in the original tube without aliquoting.
Limitations
The test has not been cleared or approved by the US Food and Drug Administration. Results need to be correlated with clinical, histopathologic, and additional laboratory findings for final patient management. No specific cautionary statements affect the reliability of testing, but proper specimen handling and processing are required.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
Result Turnaround Time
1-11 days
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
4 mL
Minimum Volume
1 mL
Container
Yellow top (ACD solution A or B); Lavender top (EDTA) or green top (heparin) acceptable
Collection Instructions
Invert several times to mix bone marrow. Send bone marrow specimen in original tube. Do not aliquot.
Causes for Rejection
Gross hemolysis; Fully clotted
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 4 days |
| Refrigerated | 4 days |